A hormone-free male birth control pill is undergoing clinical testing for the first time ever. The drug, called YCT-529, has performed incredibly well at limiting the production of sperm in mice and ...
A groundbreaking hormone-free male birth control pill, YCT-529, has transitioned from successful preclinical studies in mice to the initiation of human trials. Developed by YourChoice Therapeutics, ...
WARREN, Mich., May 21, 2025 /PRNewswire/ -- FemCap (https://femcap.com), an FDA-approved, prescription-only contraceptive device, is offering a groundbreaking alternative in the world of birth control ...
SAN DIEGO--(BUSINESS WIRE)--2024 BIO International Convention—YourChoice Therapeutics, Inc., pioneering hormone-free family planning products, has completed its first-in-human clinical study for ...
Women’s reproductive rights in the U.S. are narrowing. Meanwhile, 46% of all pregnancies in the U.S. are unintended, pointing to the stark evidence of the enduring need for access to effective, ...
Women have long shouldered the burden of birth control. Now, men may soon have an option that is not only hormone-free, but also allows space between doses. YourChoice Therapeutics on June 4 at the ...
The global hormonal contraceptives market is projected to grow from about $19.5 billion in 2017 to over $30 billion by 2026, according to a study by Transparency Market Research. If one considers the ...
YCT-529 is a retinoic acid receptor-alpha inhibitor designed to prevent sperm production by blocking access to vitamin A. A phase 1 study evaluating the first hormone-free male birth control pill, YCT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback